Cereblon binding molecules in multiple myeloma

K. M. Kortüm, Y. X. Zhu, C. X. Shi, P. Jedlowski, Alexander Keith Stewart

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Immunomodulation is an established treatment strategy in multiple myeloma with thalidomide and its derivatives lenalidomide and pomalidomide as its FDA approved representatives. Just recently the method of action of these cereblon binding molecules was deciphered and results from large phase 3 trials confirmed the backbone function of this drug family in various combination therapies. This review details the to-date knowledge concerning mechanism of IMiD action, clinical applications and plausible escape mechanisms in which cells may become resistant/refractory to cereblon binding molecule based treatment.

Original languageEnglish (US)
Pages (from-to)329-334
Number of pages6
JournalBlood Reviews
Volume29
Issue number5
DOIs
StatePublished - Sep 1 2015

Keywords

  • Aiolos
  • Cereblon
  • Cereblon binding molecules
  • Ikaros
  • IMiDs
  • Lenalidomide
  • Multiple myeloma
  • Pomalidomide
  • Thalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Cereblon binding molecules in multiple myeloma'. Together they form a unique fingerprint.

  • Cite this

    Kortüm, K. M., Zhu, Y. X., Shi, C. X., Jedlowski, P., & Stewart, A. K. (2015). Cereblon binding molecules in multiple myeloma. Blood Reviews, 29(5), 329-334. https://doi.org/10.1016/j.blre.2015.03.003